The LVAD Paradox in Heart Transplantation: Higher Risk of Primary Graft Dysfunction, Yet Improved Survival Outcomesdszcx

MedXY Editorial Team•Dec 29, 2025•Cardiology

Durable left ventricular assist device (LVAD) support is associated with a significantly higher incidence of severe primary graft dysfunction (PGD) after heart transplantation (12.7% vs 7.4%).
Paradoxically, LVAD-supported patients who develop severe PGD have a significantly lower 1-year mortality rate (28.8%) compared to non-LVAD patients with severe PGD (40.7%).
Key clinical risk factors for severe PGD in the LVAD population include elevated pre-transplant creatinine, high CVP/PCWP ratios, and prolonged donor ischemic time.
Venous congestion surrogates are more predictive of PGD in the LVAD population than traditional hemodynamic markers.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Durable left ventricular assist device (LVAD) support is associated with a significantly higher incidence of severe primary graft dysfunction (PGD) after heart transplantation (12.7% vs 7.4%).
Paradoxically, LVAD-supported patients who develop severe PGD have a significantly lower 1-year mortality rate (28.8%) compared to non-LVAD patients with severe PGD (40.7%).
Key clinical risk factors for severe PGD in the LVAD population include elevated pre-transplant creatinine, high CVP/PCWP ratios, and prolonged donor ischemic time.
Venous congestion surrogates are more predictive of PGD in the LVAD population than traditional hemodynamic markers.